Phase IIb randomized trial of adjunct immunotherapy in patients with first-diagnosed tuberculosis, relapsed and multi-drug-resistant (MDR) TB.

Paired t-test of quantitative scoring of sputum bacillary load at baseline and post-treatment revealed that the decrease in V5 group was highly significant (from mean/median 2.2 ± 0.98/3 to 0.29 ± 0.55/0; P = 6E-010) but no difference was seen in placebo recipients (1.9 ± 0.99/1.5 to 1.8 ± 1.03/1; P = 0.34).

also in 132,142 other papers